Contributions of ELN2022 update and new genetic analysis tests in the risk assesment and treatment of acute myeloid leukaemia

Abstract

Acute myeloid leukaemia (AML) is a heterogeneous disease including cytogenetic and molecular abnormalities. Age, performance status and specific genetic characteristics are important in prognosis. Both directing consolidation treatment and having genetic-based treatment targets have made genetic results even more important. The European LeukemiaNet (ELN) 2022 report was published by expanding the genetic mutation profile. In order to question what this update has changed in clinical practice, we reviewed the data of patients with acute myeloid leukaemia in whom myeloid panel was studied by Next-Generation Sequencing (NGS).